This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial.
The Journal of infectious diseases · 2026
Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis.
The European respiratory journal · 2026
Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies.
Clinical pharmacokinetics · 2026 · senior author
Latest funding
- $1,154,425
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
CIHR · 2023 · Principal investigator
- $4,617,694
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
CIHR · 2023 · Principal investigator
- $7,899,734
Tackling the two greatest obstacles to Tuberculosis elimination: Treatment of latent infection and drug resistant disease.
CIHR · 2014 · Co-investigator
10 publications.
Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial.
Gafar F, Svensson EM, Yunivita V, Fregonese F, Fisher D, Fox GJ, Nguyen TA, Nguyen BH, Johnston J, Long R, Valiquette C, Aarnoutse RE, Ruslami R, Menzies D
Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis.
Béranger A, Solans BP, Miyakawa R, McIlleron H, Tarning J, Shah I, Aruldhas BW, Mathew BS, Kwara A, Peloquin CA, Mukherjee A, Lodha R, Denti P, Capparelli EV, Kiser JJ, Bekker A, Chabala C, Choo L, Turkova A, Gafar F, Ruslami R, Nataprawira HM, Heysell SK, Thomas TA, Velpandian T, Day JN, Bang ND, Dooley K, Savic RM
Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies.
Noeriman AR, Sumarheni S, Hasanah AN, Apriani L, Santoso P, Alffenaar JC, Gafar F, Ruslami R
Inflammation and dyslipidaemia in combined diabetes and tuberculosis; a cohort study.
Brake J, Ajie M, Sumpter NA, Koesoemadinata RC, Soetedjo NNM, Santoso P, Alisjahbana B, Ruslami R, Hill P, van Crevel R
Tuberculosis.
Trajman A, Campbell JR, Kunor T, Ruslami R, Amanullah F, Behr MA, Menzies D
Clinical Features, Adverse Events and Treatment Outcomes of Multidrug/Rifampicin-resistant Tuberculosis in Children and Adolescents: An Eight-year Retrospective Cohort Study in Bandung, Indonesia.
Nataprawira HM, Gafar F, Sari CA, Alffenaar JC, Marais BJ, Ruslami R, Menzies D
Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R2 randomized controlled trial.
Gafar F, Yunivita V, Fregonese F, Apriani L, Aarnoutse RE, Ruslami R, Menzies D
Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
Yunivita V, Gafar F, Santoso P, Chaidir L, Soeroto AY, Meirina TN, Te Brake L, Menzies D, Aarnoutse RE, Ruslami R
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A
Safety and Side Effects of Rifampin versus Isoniazid in Children.
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li PZ, Hill PC, Schwartzman K, Benedetti A, Menzies D
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
Principal investigators: Menzies, Richard; Campbell, Jonathon; Fox, Gregory; Golchi, Shirin; Johnston, James C; Law, Stephanie; Long, Richard; Lupien, Andréanne; Ruslami, Rovina
Keywords: Acceptability; Adaptive Trial; Cost-Effectiveness; Multi-Arm Trial; Multicentre Trial; Randomized Trial; Safety; Tolerability; Tuberculosis; Tuberculosis Prevention
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
Principal investigators: Menzies, Richard; Campbell, Jonathon; Fox, Gregory; Golchi, Shirin; Johnston, James C; Law, Stephanie; Long, Richard; Lupien, Andréanne; Ruslami, Rovina
Keywords: Acceptability; Adaptive Trial; Cost-Effectiveness; Multi-Arm Trial; Multicentre Trial; Randomized Trial; Safety; Tolerability; Tuberculosis; Tuberculosis Prevention
Tackling the two greatest obstacles to Tuberculosis elimination: Treatment of latent infection and drug resistant disease.
Principal investigators: Menzies, Richard
Keywords: Cost Effectiveness Analysis; Drug Resistance; Infectious Disease Modeling; Latent Tuberculosis; Randomized Trial; Systematic Reviews And Meta-Analyses; Tuberculosis; Tuberculosis Prevention; Tuberculosis Treatment
A randomized trial to compare effectiveness of 4 months Rifampin (4 RIF) with 9 months Isoniazid (9 INH) in the prevention of active TB in children: The P4v9 Trial
Principal investigators: Menzies, Richard
Keywords: Child Health; Global Health; Latent Tb Infection; Randomized Trail; Tuberculosis Prevention; Tuberculosis Treatment
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medicine
- Infectious Diseases
- Respiratory Epidemiology Unit
- School of Population and Public Health
- Other
Co-authors at McGill University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Richard Long
Medicine
3 shared papers, latest 2026
Richard Long
Medicine
2 shared papers, latest 2018
Kevin Schwartzman
Respiratory Epidemiology Unit
2 shared papers, latest 2018
Andrea Benedetti
Infectious Diseases
2 shared papers, latest 2018
Kevin Schwartzman
Faculty
2 shared papers, latest 2018
Andrea Benedetti
Faculty
2 shared papers, latest 2018
James Johnston
School of Population and Public Health
1 shared papers, latest 2026
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.